Drug Profile
Research programme: personalised cancer vaccines - Moderna Therapeutics
Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Moderna Therapeutics
- Class Cancer vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 11 Apr 2018 National Cancer Institute plans a phase I/II trial for Urogenital cancer, Gastrointestinal cancer, Malignant melanoma (Metastatic disease, second line therapy or greater) in USA, in April 2018 (NCT03480152)
- 22 Sep 2017 Moderna Therapeutics plans a phase I/II trial for Cancer in USA